Pharmacy News

Image description

FDA fast-tracks Genentech’s Rituxan

Drug is intended for the treatment of pemphigus vulgaris, a painful, disfiguring and potentially fatal autoimmune disease characterized by progressive blistering of skin and/or mucous membranes.

Image description

FDA approves Parkinson’s drug

Newron Pharmaceuticals’ Xadago was approved as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes.

Image description

Analysis: Entresto improves glycemic control

Entresto lowered HbA1c levels — a measure of average blood glucose levels for the past two to three months — after one year of treatment for heart failure, according to Novartis-funded research.

Image description

Report: CVS Health says new Amgen data could expand Repatha eligibility

Based on new data about Amgen’s PCSK9 inhibitor cholesterol drug Repatha, CVS Health’s chief medical officer, Dr. Troyen Brennan, told Reuters that the number of patients eligible to use the drug could quadruple. He noted that the data — published in the New England Journal of Medicine and showing Repatha’s ability to reduce heart attack, stroke, heart disease deaths, chest pain hospitalizations and stent and bypass procedures by 15% — would need to be reviewed by heart experts. (Reuters)
 

Image description

OmniSYS acquires voiceTech, Fusion-Rx platform

OmniSYS, a medical claims billing, Medicare compliance and pharmacy patient engagement solutions company is bringing voiceTech and its Fusion-Rx platform into its suite of pharmacy solutions with a recent acquisition.